Retatrutide (GLP-3)

Retatrutide (GLP-1/GIP/Glucagon Triple Agonist)

Retatrutide is a synthetic peptide compound currently under investigation in preclinical and clinical research settings. It is a triple receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously.

In research contexts, scientists are studying retatrutide for its potential role in metabolic regulation, including its effects on energy balance, glucose metabolism, and lipid processing. Early-stage studies have also explored its influence on body composition and appetite signaling pathways.

FDA Disclaimer: Retatrutide supplied by AMYNO is intended strictly for laboratory and scientific research purposes. It is not approved by the Food and Drug Administration (FDA) for human or animal use, and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. All research involving this compound should be conducted by qualified professionals in a controlled setting and in compliance with all applicable laws and regulations.